Antiemetic therapy

DRUG2 trials

Sponsors

Saito Mitsue, Feixue Song

Conditions

Breast Cancer Breast Cancer, Chemotherapy induced nausea and vomiting (CINV)ElectroacupunctureNausea and VomitingOlanzapine-contained Four-drug Antiemetic

Phase 3

Double-blind comparative randomized Japanese trial of triplet antiemetic therapies with or without 5mg Olanzapine for AC therapy

Active, not recruitingJPRN-jRCT1031200134

Saito MitsueBreast Cancer Breast Cancer, Chemotherapy induced nausea and vomiting (CINV)

Start: 2020-10-26Target: 500Updated: 2026-06-29

Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

RecruitingNCT06314906

Feixue SongElectroacupuncture, Nausea and Vomiting, Olanzapine-contained Four-drug Antiemetic

Start: 2024-03-07End: 2027-03-31Target: 370Updated: 2024-03-21

Related Papers

Central Nervous System Symptom Burden and Clinical Implications for Antiemetic Management with Olanzapine in AC Chemotherapy.

2026-09-09

Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.

2025-06-181 citations

Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B)

BMJ Open2022-03-011 citations